Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-Dependent Humans

Condition(s) targeted: Cocaine Dependence; Depressive Symptoms

Intervention: sertraline (Drug); Placebo (Drug); gabapentin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Alison Oliveto, PhD, Principal Investigator, Affiliation: University of Arkansas

Overall contact:
Michael Mancino, MD, Phone: (501) 526-7911, Email: mjmancino@uams.edu

To examine the clinical efficacy of sertraline (200 mg/day) alone or sertraline in combination with gabapentin. The purpose of this study is to examine whether the antidepressant sertraline alone or combined with gabapentin delays time to relapse relative to placebo in recently abstinent cocaine-dependent volunteers who are also depressed. In addition, whether depressive symptoms or genetic factors influence treatment response to the study medications will be examined. Our hypothesis is that those on combined sertraline-gabapentin will show a longer period of abstinence than those on sertraline alone or placebo.

Official title: Sertraline Augmented With GABA Agents for Cocaine Dependence

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study

Primary outcome: Urine toxicology results for cocaine/metabolite or other illicit drugs

Secondary outcome: scores on Ham-D

Detailed description: Subjects enrolled in this 12-wk, double blind, randomized, placebo-controlled, clinical trial are admitted to a residential facility in North Little Rock (RCA-NLR) and randomized by depressive symptom severity to receive one of the following: sertraline alone (200 mg/day), sertraline (200 mg/day) plus gabapentin (1200 mg/day), or placebo. Subjects are expected to participate in the Substance Abuse Day Treatment Program while residing on the RCA-NLR and being inducted onto the maintenance dose of study medication (weeks 1-2). When participants transfer to the Outpatient Treatment Research Unit (TRU) at the start of their third week, they will continue to receive study medications or placebo (weeks 3-12) and they will be expected to participate in weekly individual cognitive behavioral therapy. Compliance with study requirements during weeks 3-12 will be facilitated through the use of contingency management procedures (see below), whereby subjects are given monetary compensation for attendance and for returning blister packs. Supervised urines and vital signs will be obtained thrice weekly; self-reported adverse effects, mood and drug use self-reports will be obtained once weekly. At the end of 12 weeks, participants will be tapered off the study medication over a five-day period, discharged from the study, and referred to an appropriate treatment or treatment/research program in the community if they are interested.

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18-65 years old

- not currently enrolled in a treatment program

- subjects must have a history of cocaine use, with street cocaine use by history being

a minimum of 1 gram during the preceding 3 months

- subjects must meet DSM-IV criteria for cocaine dependence as assessed by the

substance abuse section of the Structured Clinical Interview for DSM-IV (SCID and SCID-SAC)

- subjects must have laboratory confirmation of recent cocaine use (positive urine for

cocaine or benzoylecgonine) during the month prior to study entry

- subjects must score at least 15 on the Hamilton Depression Scale

- women of childbearing age must have a negative pregnancy test to enroll in this study

and must agree to monthly pregnancy testing

Exclusion Criteria:

- current diagnosis of other drug or alcohol physical dependence (other than cocaine or

tobacco)

- ill health (e. g., major cardiovascular, renal, endocrine, hepatic disorder)

- history of schizophrenia, or bipolar type I disorder

- present or recent use of over-the-counter or prescription psychoactive drug or

drug(s) that would be expected to have major interaction with drug to be tested

- medical contraindication to receiving study medications (e. g., for sertraline, use of

monoamine oxidase inhibitor within last two weeks; significant history of seizures; significant history of head trauma or serious neurological disorders)

- current suicidality or psychosis

- Liver function tests (i. e., liver enzymes) greater than three times normal levels

- pregnancy

Michael Mancino, MD, Phone: (501) 526-7911, Email: mjmancino@uams.edu

University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7911, United States; Recruiting
Alison Oliveto, Ph.D., Phone: 501-686-8969, Email: olivetoalison@uams.edu
Michael Mancino, MD, Sub-Investigator

Starting date: January 2006
Ending date: June 2009
Last updated: April 20, 2009